OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a lead-in dose escalation study to determine the safety, tolerability,
pharmacokinetics, maximum tolerated dose (MTD), and recommended Phase II dose of OPB-51602
administered on a weekly basis in subjects with advanced malignancies. Using the recommended
phase II dose, the efficacy and tolerability of OPB-51602 administered prior to definitive
chemoradiotherapy will be evaluated in locally advanced NPC patients. This study's
overarching goal is the development of STAT3 inhibitors as a novel class of anti-cancer
agents and the optimization of patient selection for STAT3 inhibitor therapy through parallel
biomarker studies. This study hopes to establish a therapeutic window for OPB-51602 in solid
tumours and will evaluate its potential as a targeted therapy of NPC, since this represents a
critical unmet clinical need. The development of predictive and pharmacodynamic biomarkers in
tandem with the clinical evaluation of OPB-51602 will be crucial to its therapeutic
advancement and will enable an understanding of the genetic contexts of responsiveness and
resistance to OPB-51602, which can in turn lead to the development of effective drug
combinations to overcome resistance.The study hypothesizes that OPB-51602, a first-in-class
STAT3 inhibitor, is efficacious in solid tumours with constitutively activated STAT3, such as
NPC.